Showing 5051-5060 of 21466 results for "".
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://reachmd.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned
- Hugo Robotic Prostatectomy Trial Meets Safety And Effectiveness Endpointshttps://reachmd.com/news/hugo-robotic-prostatectomy-trial-meets-safety-and-effectiveness-endpoints/2487868/Key Takeaways Across the three included operations, prespecified safety and effectiveness endpoints were achieved. Effectiveness was defined by freedom from conversion, and safety by 30-day Clavien-Dindo Grade ≥III complications. Major complic
- Diranersen Slows Decline in Phase 2 CELIA Trial for Early Alzheimer Diseasehttps://reachmd.com/news/diranersen-slows-decline-in-phase-2-celia-trial-for-early-alzheimer-disease/2487872/Key Takeaways After 18 months, diranersen was associated with less decline than placebo across the named clinical measures in early Alzheimer disease. The clinical signal was paired with a biomarker effect, and investigators described the result as ran
- Perioperative Systemic Therapy vs Surgery Alone in Colorectal Peritoneal Metastaseshttps://reachmd.com/news/perioperative-systemic-therapy-surgery-colorectal-peritoneal-metastases/2487859/Key Takeaways Investigators observed longer median overall survival with perioperative systemic therapy, but the survival comparison did not reach statistical significance. Safety findings included higher major postoperative morbidity after perioperati
- GB-0669 Phase 1 Trial Reports Long Half-Life, Mild Adverse Reactionshttps://reachmd.com/news/gb-0669-phase-1-trial/2487862/Key Takeaways GB-0669 was well tolerated, with no dose-limiting toxicities and only mild adverse reactions. Exposure was dose-proportional up to 2400 mg, and the half-life was 54 days. Serum live virus neutralization increased at 600 mg and 12
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://reachmd.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- Setmelanotide Lowers BMI and Hunger in Acquired Hypothalamic Obesityhttps://reachmd.com/news/setmelanotide-lowers-bmi-and-hunger-in-acquired-hypothalamic-obesity/2487850/Key Takeaways At 52 weeks, BMI changed more favorably with setmelanotide than with placebo in acquired hypothalamic obesity. Hunger scores also improved more with setmelanotide over 52 weeks. Adverse events were common, serious adverse events
- Dialectical Behavior Therapy vs Schema Therapy for Borderline Personality Disorderhttps://reachmd.com/news/dialectical-behavior-therapy-vs-schema-therapy-for-borderline-personality-disorder/2487840/Key Takeaways No statistically significant difference was observed between dialectical behavior therapy and schema therapy on the primary outcome. No significant between-group differences were reported on secondary outcomes, while both groups improved
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://reachmd.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Six-Month Strategy for Rifampicin-Resistant Tuberculosishttps://reachmd.com/news/six-month-strategy-for-rifampicin-resistant-tuberculosis/2487839/Key Takeaways At the end of treatment and at 76 weeks, successful outcomes were almost identical between groups, and the 6-month strategy met the prespecified noninferiority margin. Grade 3 or higher adverse events occurred at similar rates, and anemia